Category Archives: Op-Ed

What's the Future of European Health Policy?

What can be gleaned about the direction that health policy will take for the next five years under the new European Commission, scheduled to take office at the beginning of November? Peter O’ Donnell address this question in his new Applied Clinical Trials column here.
Also posted in Europe, Global, Guest Blog, healthcare, Regulatory | Tagged , , | Leave a comment

PPRS Payments Now Worth £150m in the UK

By Leela Barham. A second payment has now been made under the UK’s Pharmaceutical Price Regulation Scheme (PPRS). Adding a further £76m to the £74m for the first quarter of 2014, the payments received by the Department of Health (DH) now total £150m (US$244m).  Payments are a new feature of the long-standing voluntary PPRS. The […]
Also posted in Europe, Guest Blog, pricing, Regulatory | Tagged , , | Leave a comment

Managing High-Priced, US Biotech Rxs in Canada

As the “Saga of Sovaldi” continues to unfold in the U.S., and Congress, insurers, providers, and the U.S. Rx manufacturer, Gilead, hurl charges back and forth at each other, it’s pretty clear the situation will only continue to deteriorate. However, as you look north of the American border, it’s striking how Canadian healthcare entities are managing […]
Also posted in pricing | Tagged , , , , | Leave a comment

Gain Competitive Advantage: Think Like a Navy SEAL

Pharmaceutical professionals, teams, and organizations can succeed at an elite level by tackling the tough mental challenges of Navy SEAL training, writes Stan Bernard. Victorious warriors win first in their minds, and then go to war. Defeated warriors go to war first and then seek to win. — Sun Tzu, Author of The Art of War (544 BCE-496 BCE) […]
Also posted in Guest Blog, Marketing, Strategy | Tagged , , | 1 Comment

UK’s Controversial Cancer Fund Boosted — But What’s the Long-Term Plan?

By Leela Barham. The English Cancer Drugs Fund (CDF), set up to provide funding for those products that the National Institute for Health and Care Excellence (NICE) has not recommended for use or where their guidance isn’t yet available, remains controversial. Initially penciled for closure in 2014, it is now planned to run to 2016. […]
Also posted in Europe, Guest Blog, pricing | Tagged , , , , , , | Leave a comment
  • Categories

  • Meta